EBMT 2019 | Molecular techniques for monitoring MRD in AML

Torsten Haferlach

Torsten Haferlach, MD Munich Leukemia Laboratory, Munich, Germany, evaluates the different methods currently being used to monitor measurable residual disease (MRD) in acute myeloid leukemia (AML) patients. This video was recorder at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

Share this video